Home › Blood Cancers › NCT05011045
Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies
RecruitingObservational study
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Age 18 years or older * Treatment with radiation therapy to the brain for a hematologic malignancy (ex. primary central nervous system lymphoma \[PCNSL\], secondary central nervous system lymphoma \[SCNSL\], leukemia, myeloma) * Proficient and capable of completing tests in English * Patients with claustrophobia are eligible if the claustrophobia is managed with medication * Patients with cognitively-impairment are eligible if the impairment is managed with medication * Patients who are pregnant
About the study
This study assesses neurocognitive outcomes after receiving radiation therapy to the brain (whole brain radiation therapy) in patients with blood cancers (hematologic malignancies). This may help researchers learn more about the effects of whole brain radiation therapy on memory and thinking in patients with blood cancer.
What is being tested
- Magnetic Resonance Imaging (procedure)
- Neurocognitive Assessment (other)
- Quality-of-Life Assessment (other)
- Questionnaire Administration (other)
Sponsor: M.D. Anderson Cancer Center · Participants: 100 · Started: Jan 9, 2020
Contact the study team
- Dustin M Silk · Phone: 713-563-3090
Official record on ClinicalTrials.gov — NCT05011045
Locations in the U.S.
| Texas | M D Anderson Cancer Center, Houston |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.